Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viral Kinetics of PEG-IFN and Lamivudine Regimens in Chronic Hepatitis B
NCT00226447Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Dec 2002
- Primary completion
- Jul 2006
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b and lamivudine in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: HBV DNA reduction at week 52. Started Dec 2002; status: completed.
02
Drugs
peginterferon alfa-2blamivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00226447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226447.